Latest Biotech News

Page 1 of 42
IDT Australia expects FY27 revenue of $19 million to $20 million and EBITDA of $1 million to $1.5 million, marking a projected swing from a $0.92 million FY26 loss. The forecast rests on larger customer contracts, a five-year radiopharmaceutical deal and roughly $7 million of manufacturing upgrades.
Victor Sage
Victor Sage
18 Nov 2026
Actinogen Medical’s shares have been suspended while it completes analysis of additional data from its pivotal XanaMIA Alzheimer’s trial. The company expects trading to resume no later than 19 November unless the results announcement comes first.
Ada Torres
Ada Torres
17 Nov 2026
Cynata Therapeutics has lifted its proposed shareholder-approved placement to approximately $750,000, taking potential proceeds from its two-stage capital raising to about $1.663 million before costs. The biotech says key clinical and termination costs have been paid, while its externally funded kidney transplant trial remains in follow-up.
Ada Torres
Ada Torres
13 Nov 2026
Clinuvel has outlined a multi-year expansion from peptide therapeutics into polymers, long-acting injectables, devices and digital health, backed by A$220 million of planned FY2027-FY2030 spending. The strategy comes with a near-term setback: first patient treatment in the CUV107 vitiligo study has been delayed to February 2027.
Victor Sage
Victor Sage
6 Nov 2026
Clever Culture Systems has secured $2.6 million to develop APAS Revolution, a smaller benchtop system aimed at pharmaceutical manufacturers not served by its existing platform. The funding combines a discounted share placement with new debt, while commercial launch is targeted for the first half of 2028.
Victor Sage
Victor Sage
3 Nov 2026
Pathkey.AI has secured its first Chipforge customer contract ahead of the semiconductor platform’s commercial release, while a $2.8 million placement lifted quarter-end cash to $5.83 million. The company remains early-stage, with just $10,000 in customer receipts during the September quarter and further commercial conversion still to prove.
Sophie Babbage
Sophie Babbage
30 Oct 2026
Invex Therapeutics has paired its proposed acquisition of Rekover Therapeutics with a $10 million equity raising to fund a Phase 2a multiple sclerosis study and its existing Exenatide programs. The biotech ended September with A$3.59 million in cash, with shareholder approval still required for the larger part of the transaction.
Ada Torres
Ada Torres
30 Oct 2026
Recce Pharmaceuticals has cleared an active-comparator design for its pivotal Australian diabetic foot infection trial while an independent review of Indonesian Phase 3 data approaches. The biotech ended the quarter with A$1.04 million in cash, alongside expected tax rebates and unused financing facilities.
Victor Sage
Victor Sage
30 Oct 2026
Paradigm Biopharmaceuticals’ pivotal knee osteoarthritis trial fell below its pre-specified continuation threshold, leaving the ASX-listed biotech in voluntary administration with A$4.33 million in cash. Administrators now have up to three months to assess restructuring options, clinical data and the company’s future.
Victor Sage
Victor Sage
30 Oct 2026
Cynata Therapeutics will raise approximately $912,962 after shareholders subscribed for just 25.8% of its fully underwritten entitlement offer. Caravel Securities will fund the remaining shortfall, leaving the biotech reliant on the underwriter to complete the raise.
Ada Torres
Ada Torres
30 Oct 2026
Clever Culture Systems has started FY27 with three APAS Independence sales to Novo Nordisk and AstraZeneca, while targeting eight first-half sales and evaluations. The sales momentum comes with $1.6 million of unsecured loans due in December and a proposed extension still to be secured.
Victor Sage
Victor Sage
30 Oct 2026
Papyrus Australia says its second production-scale board run delivered significantly improved internal test results, with samples now sent to TBS for acceptance testing. The progress is tempered by a reported $365,000 cash balance, $447,000 in unused facilities and estimated funding for just 1.51 quarters.
Victor Sage
Victor Sage
30 Oct 2026

Browse the archive

Full archive